Rheuma Tv

Gut clues to joint damage: Intestinal permeability markers linked to erosive hand osteoarthritis

by

In a compelling new analysis published in Osteoarthritis and Cartilage, researchers identified a significant association between markers of intestinal permeability and erosive hand osteoarthritis (EHOA), providing fresh insight into the systemic factors contributing to osteoarthritis pathogenesis.   The study, based on data from the DIGICOD cohort, evaluated serum levels of four intestinal permeability biomarkers, lipopolysaccharide binding … Read more

Subcutaneous Tocilizumab, Alone or with Methotrexate, Demonstrated Superior Efficacy Over Methotrexate Monotherapy in Chinese RA Patients

by

A comprehensive phase 3 randomized clinical trial conducted across 19 Chinese medical centers has provided compelling evidence for the therapeutic superiority of subcutaneous tocilizumab (TCZ) in managing moderate to severe rheumatoid arthritis patients who had shown an insufficient response to conventional synthetic disease-modifying antirheumatic drugs. The study enrolled 340 adults aged 18–70 years, with 136 … Read more

GM-CSF Identified as Key Driver of IL-6 Production by Macrophages in Polymyalgia Rheumatica

by

A recent study published in Annals of the Rheumatic Diseases uncovered that granulocyte-macrophage colony-stimulating factor (GM-CSF) played a pivotal role in promoting IL-6 production by macrophages in polymyalgia rheumatica (PMR), reinforcing the pathogenic significance of these cells in the disease.  Investigators analyzed monocyte phenotypes in peripheral blood from 22 PMR patients and 20 healthy controls, … Read more

Deucravacitinib demonstrates broad minimal disease activity component improvements in psoriatic arthritis: Phase 2 trial results

by

Deucravacitinib, a selective oral TYK2 inhibitor, achieved significant and consistent improvements across all seven components of minimal disease activity (MDA) in patients with psoriatic arthritis (PsA), according to findings from a phase 2 trial published in Rheumatology (Oxford). The post-hoc analysis highlighted a comprehensive therapeutic response, reinforcing the potential of TYK2 inhibition in addressing the … Read more

Calprotectin emerged as a promising biomarker for disease severity in systemic sclerosis

by

Serum calprotectin demonstrated significant potential as a novel biomarker for disease severity and activity in patients with systemic sclerosis (SSc), according to findings from a monocentric cross-sectional study published in the International Journal of Molecular Sciences. Conducted at a tertiary care center in Rome, the study assessed serum calprotectin levels in 74 consecutive SSc patients … Read more

Anifrolumab Shows Durable Benefits in Achieving LLDAS and Remission in SLE: TULIP and Extension Trial Outcomes

by

Long-term treatment with anifrolumab significantly increased the likelihood of achieving lupus low disease activity state (LLDAS) and remission as defined by the DORIS criteria in patients with moderate to severe systemic lupus erythematosus (SLE), according to a post hoc analysis published in Annals of the Rheumatic Diseases. These findings are based on a combined assessment … Read more

No association between abatacept exposure levels and infection risk in early RA: AVERT-2 trial findings

by

A post-hoc analysis of the AVERT-2 trial, published in The Journal of Rheumatology, found no association between serum exposure levels of subcutaneous (SC) abatacept and infection risk in patients with early rheumatoid arthritis (RA). This analysis was based on data from the Assessing Very Early Rheumatoid Arthritis Treatment-2 (AVERT-2) randomized, placebo-controlled study, which enrolled anti-citrullinated … Read more

IL-18 emerges as a potential biomarker and therapeutic target in primary Sjögren’s Syndrome

by

A new systematic review and meta-analysis published in Medicine has highlighted the significant elevation of interleukin-18 (IL-18) in patients with primary Sjögren’s syndrome (pSS), reinforcing its role in the disease’s pathogenesis and its promise as a diagnostic and therapeutic marker.  To clarify the association between IL-18 and pSS, researchers analyzed data from 11 studies retrieved … Read more

Methylprednisolone fails to show benefit in very early systemic sclerosis: ‘Hit Hard and Early’ trial results

by

The ‘Hit Hard and Early’ randomized controlled trial published to investigate the efficacy of methylprednisolone in very early systemic sclerosis (SSc) found no significant benefit in preventing disease progression. The study aimed to determine whether glucocorticoids could induce remission by inhibiting early inflammatory processes that drive disease development.  The trial enrolled adults with puffy fingers … Read more